Login / Signup

Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma.

Zufei ZhangDaping ZhangWenchuan GuoKeenan FentonSujata NarayananShweta JainJoy JiangSharon M CastellinoKara M KellyPeter D ColeFrank G KellerAmit GargYen Lin Chia
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
No further adjustments based on age or BW are required for the BV dosage (1.8 mg/kg every 3 weeks) approved in children.
Keyphrases
  • hodgkin lymphoma
  • body weight
  • newly diagnosed
  • young adults
  • clinical trial
  • lipopolysaccharide induced
  • inflammatory response
  • gestational age
  • drug administration